Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.40 |
| ▸ | SRC | P12931 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323036 | 0.94 | DYRK1A (0.56) | DYRK1ADYRK1BFGFR1SRCEGFR | |
| SCHEMBL10324008 | 0.91 | DYRK1A (0.47) | DYRK1ADYRK1BCSF1RCCNA2CDK2 | |
| SCHEMBL10322727 | 0.82 | MERTK (0.52) | DYRK1AFGFR1SRCFGFR2FGFR4 | |
| SCHEMBL10324431 | 0.81 | DYRK1A (0.39) | DYRK1ADYRK1BFGFR1SRCEGFR | |
| SCHEMBL10324192 | 0.78 | TNKS (0.43) | DYRK1ADYRK1B | |
| SCHEMBL17910174 | 0.78 | FGFR1 (0.44) | DYRK1ADYRK1BFGFR1SRCEGFR | |
| SCHEMBL10446733 | 0.74 | DYRK1A (0.90) | DYRK1ADYRK1B | |
| Hydrochloric Acid SCHEMBL10323860 | 0.74 | DYRK1A (0.89) | DYRK1ADYRK1B | |
| SCHEMBL10446561 | 0.73 | DYRK1A (0.68) | DYRK1ADYRK1B | |
| SCHEMBL10324109 | 0.73 | DYRK1A (0.83) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DYRK1A 654/4885DYRK1B 570/4885FGFR1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.